Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities

Joel Neves Briard1, Antoine Duquette1, Romain Cayrol1

  • 1From the Department of Medicine (J.N.B.), Neuroscience (A.D., S.L.-R.), and Pathology and Cellular Biology (R.C.), Université de Montréal, Canada.

Neurology
|August 9, 2024
PubMed
Summary

A patient receiving aducanumab for Alzheimer disease developed fatal super-refractory status epilepticus due to severe amyloid-related imaging abnormalities (ARIA). Vigilance in interpreting surveillance imaging is crucial for anti-amyloid therapies.